Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saroglitazar sulfoxide
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Saroglitazar sulfoxide is an active metabolite of the drug saroglitazar. Saroglitazar itself is a novel dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist. Saroglitazar sulfoxide possesses pharmacological activity, though its activity is marginally lower than that of the parent drug. It is quantitatively measured during the clinical development of saroglitazar.
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)VEGFR2 (Vascular endothelial growth factor receptor 2)PPARA (Peroxisome proliferator-activated receptor alpha)EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on saroglitazar sulfoxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saroglitazar sulfoxide.